Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897233 | 0.99 | KDM4E (0.70) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL7913070 | 0.86 | KDM4E (0.75) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL10563413 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL7903030 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL7902779 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL2899565 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL9871030 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL2899414 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL30681912 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG | |
| SCHEMBL7913301 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-2202228-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| WO-2000078724-A2 | IMIDAZOLINDERIVATIVES THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | REN, ACE, AGT | KDM4E 1257/4885ALDH1A1 897/4885SMN1; SMN2 4704/4885 |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK1 | KDM4E 3594/4885ALDH1A1 4290/4885SMN1; SMN2 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.